eural, Genetic, and Peripheral Correlates of SSRI Pharmaco-Response

Med. Univ. Wien, Univ. Klinik für Psychiatrie und Psychotherapie0 个研究点目标入组 20 人开始时间: 2011年7月15日最近更新: 2016年12月12日

试验速览

暂无简介。

•willingness and competence to sign the informed consent form voluntarily.
•aged 18 – 45 years
•right-handedness
•a DSM-IV diagnosis of a major depressive episode by a structured clinical interview (SCID)
•a MADRS score =20 and = 30
•ability to be managed as outpatients
•ability to fulfill the criteria to undergo an MRI scan
•Caucasian subjects of European ancestry
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•previous or concurrent major medical or neurological illness
•clinically significant abnormal values in routine laboratory screening or general physical examination
•DSM-IV diagnosis of substance dependence within the past year, except for caffeine or nicotine or current substance abuse
•DSM-IV diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or an anxiety disorder as a primary diagnosis
•the use of any psychotropic drug within the last two months
•unresponsiveness of a former major depressive episode to an adequate antidepressive drug dosing of at least 6 weeks duration or any kind of therapy resistance
•a history of severe drug allergy or hypersensitivity or known hypersensitivity to escitalopram
•being acutely suicidal either indicated by a score = 5 on item 10 (suicidal thoughts) on the MADRS or a score = 4 on the HAM-D 21 (suicidal thoughts) or according to the investigator´s opinion
•failures to comply with the study protocol or to follow the instructions of the investigating team
•current pregnancy or breast feeding;
•metallic implants or other contraindications to MRI

发起方

Med. Univ. Wien, Univ. Klinik für Psychiatrie und Psychotherapie